BioAegis says its ‘inflammation regulator’ is best weapon to fight COVID-19
Monday, May 11, 2020 | By Barbara Booth
KEY POINTS:
- BioAegis Therapeutics believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), is a viable therapeutic option for patients suffering from severe lung injury due to Covid-19.
- The private clinical stage company is awaiting FDA approval to accelerate their clinical trial of plasma gelsolin therapy on Covid-19 patients.
- BioAegis discovered plasma gelsolin — an abundant, naturally occurring circulating protein found in the human body’s immune system — nearly two decades ago.
- The company has built a portfolio of therapies around this unique anti-inflammatory to treat a wide range of conditions, including influenza, pneumonia, arthritis, Alzheimer’s, lupus, inflammatory bowel disease and multiple sclerosis.
“We’ve been studying this exact same condition — not with this particular virus, but with severe flu, severe pneumonia — for years, so we feel like we are in the perfect position to treat this disease.”
Dr. Susan Levinson, BioAegis CEO